We know from preclinical research that immunosuppressive tumour microenvironments can restrain anti-tumour immunity, thereby making subsequent therapeutic interventions less effective than expected. CD40 activation has been shown to reverse immune suppression and drive antitumor T cell responses, which in turn could lead to potentially better outcomes.

What happens when patients with advanced melanoma are given a checkpoint inhibitor plus an immune agonist such as anti-CD40?

Can we help the non-responding patients to checkpoint blockade improve their outcomes and shift the long tail in survival curves up using this approach?

Subscribers can log-in to read our latest insights or you can purchase access to BSB Premium Content. 

Posted by